Financial Snapshot

Revenue
$1.819M
TTM
Gross Margin
84.77%
TTM
Net Earnings
-$7.191M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
4.25%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
-$9.344M
Q3 2024
Cash
Q3 2024
P/E
-0.5565
Apr 02, 2025 EST
Free Cash Flow
-$428.2K
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2023 2022 2021 2020 2019 2012 2011 2010 2009 2008 2007 2006 2002 2001 2000 1999 1998 1997
Revenue $1.498M $1.219M $827.3K $1.090M $1.140M $0.00 $0.00 $2.000K $6.040K $0.00 $0.00 $0.00 $8.230M $7.650M $6.560M $4.720M $1.800M $540.0K
YoY Change 22.88% 47.34% -24.1% -4.39% -100.0% -66.89% 7.58% 16.62% 38.98% 162.22% 233.33%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2023 2022 2021 2020 2019 2012 2011 2010 2009 2008 2007 2006 2002 2001 2000 1999 1998 1997
Revenue $1.498M $1.219M $827.3K $1.090M $1.140M $0.00 $0.00 $2.000K $6.040K $0.00 $0.00 $0.00 $8.230M $7.650M $6.560M $4.720M $1.800M $540.0K
Cost Of Revenue $284.4K $262.7K $108.7K $210.0K $290.0K $0.00 $0.00 $0.00 $56.71K
Gross Profit $1.213M $956.2K $718.6K $880.0K $850.0K $0.00 $0.00 $2.000K -$50.67K
Gross Profit Margin 81.01% 78.45% 86.86% 80.73% 74.56% 100.0% -838.91%

Selling, General & Admin Expense

Research & Development

No data

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operating Profits/Loss YoY Change

Operating Earnings to Gross Profit Ratio

Operating Profit Margin

Operational Expenses

Concept 2023 2022 2021 2020 2019 2012 2011 2010 2009 2008 2007 2006 2002 2001 2000 1999 1998 1997
Selling, General & Admin $9.785M $9.022M $1.260M $1.160M $50.00K $130.0K $167.9K $230.3K $0.00 $0.00 $0.00 $8.910M $9.020M $8.390M $7.020M $2.110M $610.0K
YoY Change 8.46% 8.62% -61.54% -22.57% -27.1% -1.22% 7.51% 19.52% 232.7% 245.9%
% of Gross Profit 806.46% 943.57% 143.18% 136.47% 8395.0%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $17.24K $349.9K $313.8K $0.00 $0.00 $0.00 $4.610K $0.00 $110.0K $340.0K $340.0K $300.0K $110.0K $20.00K
YoY Change -95.07% 11.48% -100.0% -67.65% 0.0% 13.33% 172.73% 450.0%
% of Gross Profit 1.42% 36.59% 43.67% 0.0% 230.5%
Operating Expenses $9.786M $9.022M $8.458M $1.260M $1.160M $50.00K $130.0K $172.5K $234.7K $10.00K $0.00 $0.00 $9.020M $9.360M $8.650M $8.710M $2.180M $610.0K
YoY Change 8.47% 6.67% 571.3% 8.62% -61.54% -24.64% -26.5% 2247.1% -3.63% 8.21% -0.69% 299.54% 257.38%
Operating Profit -$8.573M -$8.066M -$7.740M -$380.0K -$310.0K -$50.00K -$130.0K -$170.5K -$285.4K
YoY Change 6.28% 4.22% 1936.78% 22.58% -61.54% -23.76% -40.25%
Operating Profit To Gross Profit -706.54% -843.57% -1077.12% -43.18% -36.47% -8525.5%
Operating Profit To Revenue -572.37% -661.77% -935.59% -34.86% -27.19% -8525.5% -4724.83%

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2012 2011 2010 2009 2008 2007 2006 2002 2001 2000 1999 1998 1997
Interest Expense $614.0K $324.4K $157.3K -$10.00K -$10.00K $0.00 $0.00 $0.00 -$400.0K -$160.0K -$90.00K -$520.0K $0.00 -$10.00K
YoY Change 89.29% 106.18% -1673.3% 0.0% 150.0% 77.78% -82.69% -100.0%
% of Operating Profit
Other Income/Expense, Net -$2.529M -$1.985M -$678.9K $0.00 -$20.00K $0.00
YoY Change 27.4% 192.33% -100.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2012 2011 2010 2009 2008 2007 2006 2002 2001 2000 1999 1998 1997
Pretax Income -$11.10M -$10.05M -$8.419M -$260.0K -$330.0K -$50.00K -$130.0K -$170.5K -$285.4K -$10.00K $0.00 $0.00 -$1.190M -$1.860M -$2.180M -$7.760M -$400.0K -$70.00K
YoY Change 10.45% 19.39% 3137.96% -21.21% -61.54% -23.76% -40.25% 2753.8% -36.02% -14.68% -71.91% 1840.0% 471.43%
Income Tax $2.033K $674.3K -$666.6K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$11.10M -$10.73M -$7.752M -$130.0K -$160.0K -$50.00K -$130.0K -$170.5K -$285.4K -$10.00K $0.00 $0.00 -$1.190M -$870.0K -$2.180M -$7.760M -$400.0K -$70.00K
YoY Change 3.53% 38.35% 5863.15% -18.75% -61.54% -23.76% -40.25% 2753.8% 36.78% -60.09% -71.91% 1840.0% 471.43%
Net Earnings / Revenue -741.33% -879.92% -937.07% -11.93% -14.04% -8525.5% -4724.83% -14.46% -11.37% -33.23% -164.41% -22.22% -12.96%
Basic Earnings Per Share -$0.28 -$0.46
Diluted Earnings Per Share -$0.28 -$0.28 -$0.46 -$5.013K -$6.170K -$59.52K -$1.625M -$289.0M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2012 2011 2010 2009 2008 2007 2006 2002 2001 2000 1999 1998 1997
Cash & Short-Term Investments $1.000M $1.050M $10.00K $0.00 $0.00 $30.00 $0.00 $0.00 $0.00 $260.0K $420.0K $460.0K $400.0K $200.0K $90.00K
YoY Change 10400.0% -100.0% -38.1% -8.7% 15.0% 100.0% 122.22%
Cash & Equivalents $751.0K $1.040M $0.00 $0.00 $0.00 $260.0K $420.0K $460.0K $400.0K $200.0K $90.00K
Short-Term Investments $249.1K $10.00K $10.00K
Other Short-Term Assets $230.0K $230.0K $228.6K $228.6K $14.40M $4.220M $4.330M $2.720M $140.0K $0.00
YoY Change 0.0% 0.62% 0.0% 241.23% -2.54% 59.19% 1842.86%
Inventory
Prepaid Expenses
Receivables $525.1K $590.0K $720.0K $520.0K $150.0K $290.0K $220.0K $50.00K $10.00K
Other Receivables $200.7K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Total Short-Term Assets $1.726M $1.640M $730.0K $230.0K $230.0K $228.6K $228.6K $0.00 $0.00 $15.17M $4.790M $5.080M $3.330M $390.0K $90.00K
YoY Change 124.66% 0.0% 0.61% 0.01% 216.7% -5.71% 52.55% 753.85% 333.33%
Property, Plant & Equipment $395.8K $0.00 $0.00 $210.00 $3.390K $260.0K $360.0K $370.0K $440.0K $260.0K $60.00K
YoY Change -100.0% -93.81% -27.78% -2.7% -15.91% 69.23% 333.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00 $0.00 $1.000K $1.000K $70.00K $0.00 $0.00 $110.0K $70.00K $70.00K $560.0K $70.00K $30.00K
YoY Change -100.0% 0.0% -98.57% 57.14% 0.0% -87.5% 700.0% 133.33%
Total Long-Term Assets $1.214M $0.00 $0.00 $100.0K $100.0K $101.2K $104.4K $4.840M $4.840M $5.200M $5.520M $5.530M $6.470M $3.920M $90.00K
YoY Change 0.0% -1.2% -3.05% 0.0% -5.8% -0.18% -14.53% 65.05% 4255.56%
Total Assets $2.940M $1.640M $730.0K $330.0K $330.0K $329.8K $333.0K $4.910M $4.840M $4.840M $20.37M $10.31M $10.61M $9.800M $4.310M $180.0K
YoY Change
Accounts Payable $738.4K $930.0K $760.0K $110.0K $100.0K $85.00K $70.09K $490.0K $590.0K $650.0K $400.0K $170.0K $20.00K
YoY Change 22.37% 10.0% 17.65% 21.27% -16.95% -9.23% 62.5% 135.29% 750.0%
Accrued Expenses $648.9K $120.0K $140.0K $78.32K $39.90K $1.890M $1.470M $1.030M $420.0K $50.00K $20.00K
YoY Change -14.29% 78.75% 96.29% 28.57% 42.72% 145.24% 740.0% 150.0%
Deferred Revenue
YoY Change
Short-Term Debt $140.3K $240.0K $230.0K $0.00 $0.00 $0.00 $0.00 $0.00 $13.21M $3.390M $4.110M $3.010M $0.00 $0.00
YoY Change 4.35% 289.68% -17.52% 36.54%
Long-Term Debt Due $5.300K $0.00 $0.00 $10.00K $0.00 $40.00K $30.00K $10.00K $10.00K
YoY Change -100.0% 33.33% 200.0% 0.0%
Total Short-Term Liabilities $1.533M $1.170M $1.000M $230.0K $260.0K $185.0K $110.0K $10.00K $20.00K $10.00K $16.65M $6.350M $5.830M $3.870M $230.0K $50.00K
YoY Change 17.0% -11.54% 40.58% 68.15% 999.9% -50.0% 100.0% 162.2% 8.92% 50.65% 1582.61% 360.0%
Long-Term Debt $2.767M $20.00K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $10.00K $0.00 $1.170M $1.810M $10.00K $20.00K
YoY Change -100.0% -35.36% 18000.0% -50.0%
Other Long-Term Liabilities $283.1K $60.00K $60.00K $55.30K $32.40K
YoY Change 0.0% 8.5% 70.68%
Total Long-Term Liabilities $3.050M $20.00K $0.00 $60.00K $60.00K $55.30K $32.40K $0.00 $0.00 $0.00 $10.00K $0.00 $1.170M $1.810M $10.00K $20.00K
YoY Change 0.0% 8.5% 70.68% -100.0% -35.36% 18000.0% -50.0%
Total Liabilities $4.581M $900.0K $840.0K $290.0K $320.0K $240.3K $142.4K $10.00K $20.00K $10.00K $16.65M $6.350M $7.000M $5.680M $240.0K $70.00K
YoY Change 7.14% -9.38% 33.19% 68.73% 1323.9% -50.0% 100.0% 162.2% -9.29% 23.24% 2266.67% 242.86%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021 2020 2019 2012 2011 2010 2009 2008 2007 2006 2002 2001 2000 1999 1998 1997
Basic Shares Outstanding 39.97M shares 38.79M shares 16.99M shares
Diluted Shares Outstanding 39.97M shares 38.79M shares 16.99M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $4.0015 Million

About Optimus Healthcare Services Inc

Optimus Healthcare Services, Inc. engages in acquiring controlling interests in healthcare-related businesses. The company is headquartered in Westbury, New York and currently employs 12 full-time employees. CRA provides services to a team of dedicated oncologists across the Tri-State area that are united by a shared commitment to conduct clinical research. CRA provides independent, community-based oncology practices and hospitals in diverse communities with the necessary infrastructure and support to enroll their patients in clinical trials without the patients having to leave their physicians' offices, hospitals or their local communities. CRA's focus is on oncology practices, as well as hospitals in diverse communities. CRA contracts with pharmaceutical companies and Contract Research Organizations (CRO) to conduct clinical trials (Phases I-IV) for investigational new drugs, biologics and medical devices. CRA's customers consist primarily of large and mid-sized pharmaceutical and biotech companies.

Industry: Services-Commercial Physical & Biological Research Peers: